We are live on ! Find out more
NLVP

New Leaf Venture Partners Portfolio holdings

AUM $43M
1-Year Est. Return 25.55%
This Fund
S&P 500
This Quarter Est. Return
-14.71%
1 Year Est. Return
-25.55%
3 Year Est. Return
+17.13%
5 Year Est. Return
+114.46%
10 Year Est. Return
+1,011.57%
AUM
$248M
AUM Growth
-$100M
Cap. Flow
-$14.1M
Cap. Flow %
-5.67%
Top 10 Hldgs %
93.2%
Holding
20
New
–
Increased
1
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
CHMA
Chiasma, Inc. Common Stock
CHMA
+$1.92M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$14.9M
2
STIM icon
Neuronetics
STIM
+$1.04M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DCPH
1
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$62.1M 25%
1,209,571
– –
ARVN icon
2
Arvinas
ARVN
$524M
$53.9M 21.72%
2,283,048
– –
HARP
3
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$49.6M 20%
292,141
– –
PASG icon
4
Passage Bio
PASG
$15.7M
$32.7M 13.19%
124,896
– –
APTX
5
DELISTED
Aptinyx Inc. Common Stock
APTX
$11.1M 4.48%
3,290,079
– –
CHMA
6
DELISTED
Chiasma, Inc. Common Stock
CHMA
$4.88M 1.97%
1,135,700
+400,000
+54% +$1.92M
ARAV
7
DELISTED
Aravive, Inc. Common Stock
ARAV
$4.45M 1.79%
946,423
– –
SRRA
8
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$4.37M 1.76%
409,611
– –
TECX
9
Tectonic Therapeutic
TECX
$579M
$4.11M 1.66%
26,296
– –
COGT icon
10
Cogent Biosciences
COGT
$6.82B
$4.04M 1.63%
448,886
– –
ALEC icon
11
Alector
ALEC
$167M
$3.58M 1.44%
339,569
– –
CMRX
12
DELISTED
Chimerix, Inc.
CMRX
$3.36M 1.35%
1,350,000
– –
XFOR icon
13
X4 Pharmaceuticals
XFOR
$366M
$2.27M 0.91%
11,167
– –
OBSV
14
DELISTED
ObsEva SA Ordinary Shares
OBSV
$2.23M 0.9%
900,501
– –
CRNX icon
15
Crinetics Pharmaceuticals
CRNX
$8.86B
$2.21M 0.89%
141,000
– –
ITRM
16
DELISTED
Iterum Therapeutics
ITRM
$1.53M 0.62%
97,087
– –
NERV icon
17
Minerva Neurosciences
NERV
$196M
$1.43M 0.58%
56,188
– –
PDSB icon
18
PDS Biotechnology
PDSB
$38.6M
$273K 0.11%
117,242
– –
STIM icon
19
Neuronetics
STIM
$125M
– –
-540,317
Closed -$1.04M
PRNB
20
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
– –
-249,774
Closed -$14.9M

Similar funds

BAM
Broadcrest Asset Management Winter Park, Florida $44.1M AUM 4.51% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
WCPI
Wynnchurch Capital Partners IV Rosemont, Illinois $44.8M AUM 11.91% 1-Year Est. Return
WAMC
Western Asset Management Company Pasadena, California $45.2M AUM 6.96% 1-Year Est. Return
CC
Corton Capital Carrying Place, Ontario, Canada $40.7M AUM 52.32% 1-Year Est. Return
CIEP
Constellation Investimentos e Participacoes Sao Paulo, Brazil $46.7M AUM 23.3% 1-Year Est. Return
IPI
Inflection Point Investments London, United Kingdom $46.9M AUM 18.35% 1-Year Est. Return
VSAM
Value Star Asset Management Hong Kong $49.2M AUM 60.1% 1-Year Est. Return

New Leaf Venture Partners's Q3 2020 Portfolio in Review

As of Q3 2020, New Leaf Venture Partners held 20 positions worth $248M, down 29% from $349M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

New Leaf Venture Partners withdrew a net $14.1M in Q3 2020, closing 2 positions. Its most notable exit was Principia Biopharma Inc. Common Stock, an estimated $14.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, New Leaf Venture Partners added an estimated $1.92M to Chiasma, Inc. Common Stock.

  • New Leaf Venture Partners added most to Chiasma, Inc. Common Stock in Q3 2020, an estimated $1.92M increase.
  • New Leaf Venture Partners fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $14.9M.
  • New Leaf Venture Partners's ten largest holdings make up 93% of its $248M portfolio in Q3 2020.
  • New Leaf Venture Partners opened 0 new positions and closed 2 in Q3 2020.
  • New Leaf Venture Partners's portfolio value fell 29% quarter-over-quarter to $248M.

Based on New Leaf Venture Partners's 13F filing for Q3 2020, filed 12 Nov 2020.